EGFR and glioblastoma: To date, different inhibitors of the PI3K/mTOR pathway, hepatocyte growth factor receptor (MET gene), fibroblast, epidermal, and vascular endothelial growth factors receptors (FGFR, EGFR, and VEGFR, respectively) are being investigated for GBM treatment, but only VEGF antibody bevacizumab improved the progression-free survival of GBM patients [35].